$ABOS

Acumen Pharmaceuticals (ABOS) will report Q3 financial results on Oct. 26, 2026, and host a conference call at 8:00 a.m. ET. The company is developing Alzheimer’s treatments, with its lead candidate, sabirnetug, in a Phase 2 trial. Acumen is also exploring a subcutaneous formulation and collaborating on a brain delivery technology. The webcast will be available live and archived on the company's website.

Acumen Pharmaceuticals, Inc. (ABOS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights • Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 • Two cand

Acumen Pharmaceuticals (NASDAQ: ABOS) reported at AAIC 2026 that its Enhanced Brain Delivery (EBD) bispecific antibodies, developed with JCR Pharmaceuticals, showed higher brain penetration than native anti-AβO antibodies in mouse and non-human primate studies. ACU401 had up to 40-fold higher frontal cortex exposure in primates and no anemia signals. The company also shared ALTITUDE-AD patient experience findings; topline results are expected in late 2026.

Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will report its first quarter 2026 financial results on Tuesday, May 12, 2026, followed by a conference call and live audio webcast at 8:00 a.m. ET. The company will provide a business and financial update during this event. Investors need to register in advance to receive dial-in numbers, and an archived recording will be available on their Investors website for at least 30 days.

RA CAPITAL MANAGEMENT, L.P. acquired an additional 6,169,606 shares of Acumen Pharmaceuticals Inc (ABOS) on March 13, 2026, increasing their total holdings to 21,101,669 shares at $3.27 per share. This transaction significantly bolsters RA CAPITAL MANAGEMENT, L.P.'s position, with Acumen Pharmaceuticals now representing 29.50% of their portfolio, demonstrating confidence in the biopharmaceutical company despite recent stock declines and profitability challenges. Acumen Pharmaceuticals is a clinical-stage company focused on developing treatments for Alzheimer's disease.

This article lists 12 healthcare stocks experiencing significant movement in Monday's pre-market session. It highlights both gainers and losers, providing their current stock prices, percentage changes, and market capitalizations. Companies like Acumen Pharmaceuticals and Dermata Therapeutics saw gains, while 60 Degrees Pharmaceuticals and Revolution Medicines experienced declines.

NEWTON, Mass., Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Acumen Pharmaceuticals, Inc. ABOS, a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will ...

NEWTON, Mass., July 28, 2025 ( GLOBE NEWSWIRE ) -- Acumen Pharmaceuticals, Inc.

NEWTON, Mass., July 10, 2025 ( GLOBE NEWSWIRE ) -- Acumen Pharmaceuticals, Inc. ( NASDAQ: ABOS ) , a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers ( AβOs ) for the treatment of Alzheimer's disease ( AD ) , will present new ...